Posters/Publications

paper

TVB-2640 (FASN inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled Ph2a trial

Gastroenterology

Date - 07/2021
poster

Analysis of non-invasive biomarker tests in the Phase 2 FASCINATE-1 study of FASN inhibitor TVB-2640

EASL International Liver Congress

Date - 06/2021
paper

First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors

EClinicalMedicine

Date - 04/2021
oral

Novel, first-in-class, fatty acid synthase inhibitor, TVB-2640 versus placebo demonstrates clinically significant reduction in liver fat by MRI-PDFF in NASH

AASLD

Date - 11/2020
oral

TVB-2640 with Bevacizumab in Relapsed High-grade Astrocytoma

European Society for Medical Oncology (ESMO) Congress

Date - 09/2020
oral

Novel, first-in-class, fatty acid synthase inhibitor, TVB-2640 versus placebo demonstrates clinically significant reduction in liver fat by MRI-PDFF in NASH

EASL International Liver Congress

Date - 08/2020
poster

The FASN inhibitor TVB-2640 is efficacious in a new 3D human liver microtissue model of NASH

EASL International Liver Congress

Date - 08/2020
paper

Fatty Acid Synthase Inhibitor TVB-2640 Reduces Hepatic de Novo Lipogenesis in Males With Metabolic Abnormalities

Hepatology 2020

Date - 07/2020
oral

FASN inhibitor TVB-2640 in NASH

NASH-TAG

Date - 01/2020
poster

Updated Results from a Prospective Phase 2 Study in Patients with First Relapse of High-grade Astrocytoma Using TVB-2640 in Combination with bevacizumab

ASCO

Date - 06/2019
Site map
Contact us

Business Development
bd@sagimet.com

Investors
ir@sagimet.com

Media
media@sagimet.com

Human Resources
hr@sagimet.com

© 2025 Sagimet Biosciences. All Rights Reserved. Terms of Use Agreement | Privacy Policy | Clinical Trial Privacy Notice

Scroll to Top